FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103293478> ?p ?o ?g. }

• W2103293478 endingPage "1585" @default.
• W2103293478 startingPage "1577" @default.
• W2103293478 abstract "Background Optimum duration of dual antiplatelet treatment (DAPT) after coronary stenting remains uncertain, with an unknown efficacy to safety ratio of extended treatment leading to discrepancies between international guidelines and clinical practice. We assessed whether DAPT continuation beyond 1 year after coronary stenting is beneficial. Methods This analysis was a planned extension of the previously published ARCTIC-Monitoring trial, in which we randomly allocated 2440 patients to a strategy of platelet function testing with antiplatelet treatment adjustment or a conventional strategy after coronary stenting with drug-eluting stent (DES). We recruited patients (aged 18 years or older) scheduled for planned DES implantation at 38 centres in France. After 1 year of follow-up, patients without contraindication to interruption of DAPT were eligible for a second randomisation to this second phase of the study (ARCTIC-Interruption). Using a computer-generated randomisation sequence (1:1; stratified by centre), we allocated patients to a strategy of interruption of DAPT where the thienopyridine was interrupted and single aspirin antiplatelet treatment was maintained (interruption group) or a strategy of DAPT continuation for 6–18 months (continuation group). The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularisation, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00827411. Findings Between Jan 4, 2011, and March 3, 2012, 1259 eligible patients were randomly allocated to treatment in ARCTIC-Interruption: 624 to the interruption group and 635 to the continuation group. After a median follow-up of 17 months (IQR 15–18), the primary endpoint occurred in 27 (4%) patients in the interruption group and 24 (4%) patients in the continuation group (hazard ratio [HR] 1·17 [95% CI 0·68–2·03]; p=0·58). STEEPLE major bleeding events occurred more often in the continuation group (seven [1%] patients) compared with the interruption group (one [<0·5%] patient; HR 0·15 [0·02–1·20]; p=0·073). Major or minor bleedings were also more common in the continuation group compared with the interruption group (12 [2%] patients vs three [1%] patients; HR 0·26 [0·07–0·91]; p=0·04). Interpretation Our finding suggests no apparent benefit but instead harm with extension of DAPT beyond 1 year after stenting with DES when no event has occurred within the first year after stenting. No conclusion can be drawn for high-risk patients who could not be randomised. The consistency between findings from all trials of such interruption suggests the need for a reappraisal of guidelines for DAPT after coronary stenting towards shorter duration of treatment. Funding Allies in Cardiovascular Trials Initiatives and Organized Networks (ACTION Study Group), Fondation de France, Sanofi-Aventis, Cordis, Medtronic, Boston Scientific, Fondation SGAM. Optimum duration of dual antiplatelet treatment (DAPT) after coronary stenting remains uncertain, with an unknown efficacy to safety ratio of extended treatment leading to discrepancies between international guidelines and clinical practice. We assessed whether DAPT continuation beyond 1 year after coronary stenting is beneficial. This analysis was a planned extension of the previously published ARCTIC-Monitoring trial, in which we randomly allocated 2440 patients to a strategy of platelet function testing with antiplatelet treatment adjustment or a conventional strategy after coronary stenting with drug-eluting stent (DES). We recruited patients (aged 18 years or older) scheduled for planned DES implantation at 38 centres in France. After 1 year of follow-up, patients without contraindication to interruption of DAPT were eligible for a second randomisation to this second phase of the study (ARCTIC-Interruption). Using a computer-generated randomisation sequence (1:1; stratified by centre), we allocated patients to a strategy of interruption of DAPT where the thienopyridine was interrupted and single aspirin antiplatelet treatment was maintained (interruption group) or a strategy of DAPT continuation for 6–18 months (continuation group). The primary endpoint was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularisation, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00827411. Between Jan 4, 2011, and March 3, 2012, 1259 eligible patients were randomly allocated to treatment in ARCTIC-Interruption: 624 to the interruption group and 635 to the continuation group. After a median follow-up of 17 months (IQR 15–18), the primary endpoint occurred in 27 (4%) patients in the interruption group and 24 (4%) patients in the continuation group (hazard ratio [HR] 1·17 [95% CI 0·68–2·03]; p=0·58). STEEPLE major bleeding events occurred more often in the continuation group (seven [1%] patients) compared with the interruption group (one [<0·5%] patient; HR 0·15 [0·02–1·20]; p=0·073). Major or minor bleedings were also more common in the continuation group compared with the interruption group (12 [2%] patients vs three [1%] patients; HR 0·26 [0·07–0·91]; p=0·04). Our finding suggests no apparent benefit but instead harm with extension of DAPT beyond 1 year after stenting with DES when no event has occurred within the first year after stenting. No conclusion can be drawn for high-risk patients who could not be randomised. The consistency between findings from all trials of such interruption suggests the need for a reappraisal of guidelines for DAPT after coronary stenting towards shorter duration of treatment." @default.
• W2103293478 created "2016-06-24" @default.
• W2103293478 creator A5016160566 @default.
• W2103293478 creator A5020604405 @default.
• W2103293478 creator A5023572557 @default.
• W2103293478 creator A5027244910 @default.
• W2103293478 creator A5032224302 @default.
• W2103293478 creator A5032245948 @default.
• W2103293478 creator A5037423816 @default.
• W2103293478 creator A5043059347 @default.
• W2103293478 creator A5043811212 @default.
• W2103293478 creator A5044982545 @default.
• W2103293478 creator A5047914225 @default.
• W2103293478 creator A5052746771 @default.
• W2103293478 creator A5056994868 @default.
• W2103293478 creator A5061332273 @default.
• W2103293478 creator A5061992582 @default.
• W2103293478 creator A5063227816 @default.
• W2103293478 creator A5065537677 @default.
• W2103293478 creator A5067624028 @default.
• W2103293478 creator A5075309186 @default.
• W2103293478 creator A5082791899 @default.
• W2103293478 creator A5085309752 @default.
• W2103293478 creator A5088096181 @default.
• W2103293478 creator A5088161654 @default.
• W2103293478 date "2014-11-01" @default.
• W2103293478 modified "2023-10-18" @default.
• W2103293478 title "Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial" @default.
• W2103293478 cites W1433020779 @default.
• W2103293478 cites W151500055 @default.
• W2103293478 cites W1936833235 @default.
• W2103293478 cites W1973598956 @default.
• W2103293478 cites W1980915088 @default.
• W2103293478 cites W1985483330 @default.
• W2103293478 cites W1990018236 @default.
• W2103293478 cites W2000030123 @default.
• W2103293478 cites W2015825692 @default.
• W2103293478 cites W2032756488 @default.
• W2103293478 cites W2076602637 @default.
• W2103293478 cites W2079818105 @default.
• W2103293478 cites W2081613030 @default.
• W2103293478 cites W2100209149 @default.
• W2103293478 cites W2101986337 @default.
• W2103293478 cites W2103798714 @default.
• W2103293478 cites W2106820552 @default.
• W2103293478 cites W2109100788 @default.
• W2103293478 cites W2121956076 @default.
• W2103293478 cites W2133536883 @default.
• W2103293478 cites W2141192690 @default.
• W2103293478 cites W2145323902 @default.
• W2103293478 cites W2146743728 @default.
• W2103293478 cites W2150086052 @default.
• W2103293478 cites W2151468302 @default.
• W2103293478 cites W2159337926 @default.
• W2103293478 cites W2167678178 @default.
• W2103293478 cites W2232858378 @default.
• W2103293478 cites W3030817736 @default.
• W2103293478 cites W90678752 @default.
• W2103293478 doi "https://doi.org/10.1016/s0140-6736(14)60612-7" @default.
• W2103293478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25037988" @default.
• W2103293478 hasPublicationYear "2014" @default.
• W2103293478 type Work @default.
• W2103293478 sameAs 2103293478 @default.
• W2103293478 citedByCount "263" @default.
• W2103293478 countsByYear W21032934782014 @default.
• W2103293478 countsByYear W21032934782015 @default.
• W2103293478 countsByYear W21032934782016 @default.
• W2103293478 countsByYear W21032934782017 @default.
• W2103293478 countsByYear W21032934782018 @default.
• W2103293478 countsByYear W21032934782019 @default.
• W2103293478 countsByYear W21032934782020 @default.
• W2103293478 countsByYear W21032934782021 @default.
• W2103293478 countsByYear W21032934782022 @default.
• W2103293478 countsByYear W21032934782023 @default.
• W2103293478 crossrefType "journal-article" @default.
• W2103293478 hasAuthorship W2103293478A5016160566 @default.
• W2103293478 hasAuthorship W2103293478A5020604405 @default.
• W2103293478 hasAuthorship W2103293478A5023572557 @default.
• W2103293478 hasAuthorship W2103293478A5027244910 @default.
• W2103293478 hasAuthorship W2103293478A5032224302 @default.
• W2103293478 hasAuthorship W2103293478A5032245948 @default.
• W2103293478 hasAuthorship W2103293478A5037423816 @default.
• W2103293478 hasAuthorship W2103293478A5043059347 @default.
• W2103293478 hasAuthorship W2103293478A5043811212 @default.
• W2103293478 hasAuthorship W2103293478A5044982545 @default.
• W2103293478 hasAuthorship W2103293478A5047914225 @default.
• W2103293478 hasAuthorship W2103293478A5052746771 @default.
• W2103293478 hasAuthorship W2103293478A5056994868 @default.
• W2103293478 hasAuthorship W2103293478A5061332273 @default.
• W2103293478 hasAuthorship W2103293478A5061992582 @default.
• W2103293478 hasAuthorship W2103293478A5063227816 @default.
• W2103293478 hasAuthorship W2103293478A5065537677 @default.
• W2103293478 hasAuthorship W2103293478A5067624028 @default.
• W2103293478 hasAuthorship W2103293478A5075309186 @default.
• W2103293478 hasAuthorship W2103293478A5082791899 @default.
• W2103293478 hasAuthorship W2103293478A5085309752 @default.
• W2103293478 hasAuthorship W2103293478A5088096181 @default.
• W2103293478 hasAuthorship W2103293478A5088161654 @default.

• next